REHOVOT, Israel and NEW YORK, Nov. 14, 2019 (GLOBE NEWSWIRE) -- Todos Medical Ltd. (OTCQB: TOMDF), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer and neurodegenerative disorders, and Amarantus Bioscience Holdings, Inc. a US-based JLABS-alumnus biotechnology holding company developing proprietary orphan neurologic, regenerative medicine and ophthalmic therapies and diagnostics through its subsidiaries, today announced that their joint venture company, Breakthrough Diagnostics, Inc. has completed enrollment of its ongoing clinical trial evaluating the relationship of Alzheimers blood diagnostic Lymphocyte Proliferation Test (LymPro Test) with amyloid PET neuroimaging at Leipzig University in Germany (the LymPro PET 2). Topline results are expected before the end of the first quarter of 2020.

Breakthrough completed a 20-subject clinical study (LymPro PET 1) in 2018 evaluating the correlation between LymPro scores and the diagnosis of Alzheimers disease, as confirmed with amyloid PET neuroimaging and other Alzheimers disease biomarkers. LymPro measures cell cycle dysregulation in peripheral lymphocytes. The top-line data, announced in July 2019, revealed a strong and statistically significant correlation between LymPro scores and amyloid PET neuroimaging cSUVR scores (r = -0.849; p = 0.00000216). Breakthroughs academic collaborators at the Leipzig University then expanded enrollment of that study to include an additional cohort of 20 subjects (LymPro PET 2) to confirm the strong relationship seen from LymPro PET 1. The data from both LymPro 1 and LymPro 2 will be published together in a peer-reviewed journal in 2020.

LymPro is a unique immune system-based Alzheimers blood test, said Dr. Herman Weiss, President & CEO of Todos. LymPro could prove to be a major breakthrough for Alzheimers disease diagnosis by measuring cell cycle dysregulation and amyloid, together, conveniently as part of a blood workup in routine clinical practice. The therapeutic field in Alzheimers has begun to see some renewed hope based upon recent Aducanumab data announced by Biogen that is directly related to the amyloid hypothesis, as well as conditional approval by the National Medical Products Administration in China for the first new Alzheimers drug in over 20 years, called Oligomannate from Shanghai Green Valley Pharmaceuticals, that is based on gut-brain biology of the microbiome and its effects on the immune system. We believe this renewed optimism and broadening of pathophysiological hypotheses relevant to Alzheimers disease being evaluated in the clinic significantly increases the scope for LymPro pharma services collaborations and begins to refine LymPros clinical utility profile for primary care physicians as strategies to correct cell cycle dysregulation emerge.

About Alzheimer's DiseaseAccording to the Alzheimer's Association, it is estimated that over 5.4 million people in the United States suffer from Alzheimer's disease. Over 500,000 patients are diagnosed annually, with nearly one-in-eight older Americans affected by the disease. Alzheimer's disease is the third leading cause of death in the United States. The cost of unpaid care in the United States is estimated at over $210 billion annually.Total payments for care are estimated at over $200 billion annually, including $140 billion in cost to Medicare and Medicaid. Alzheimer's expenditures in the United States are expected to exceed $1.2 trillion by 2050. There is no cure or effective treatment for Alzheimer's disease. Worldwide, about 35.6 million individuals have the disease and, according to the World Health Organization, the number will double every 20 years to 115.4 million people with Alzheimer's by 2050.

About Dr. Arendt's Research at Leipzig UniversityDr. Thomas Arendt is Professor of Neuroscience at Leipzig University where he runs the Paul Flechsig Institute of Brain Research. He has a 30-year record in R&D of therapeutic and diagnostic strategies of neurodegenerative disorders and made several seminal contributions to therapeutic concepts of Alzheimer's disease, including stem cell therapy and modulating tumor suppressor genes. In the early 1980's, he was involved in identifying the degeneration of the cholinergic system in Alzheimer's disease laying the basis for today's only available treatment. He is one of the pioneers of the "cell-cycle theory" of Alzheimer's disease, which he developed towards a diagnostic and therapeutic concept.

About Breakthrough Diagnostics, Inc.Breakthrough Diagnostics, Inc. is a joint venture owned by Amarantus Bioscience Holdings, Inc. (OTCPK: AMBS) (80.01%) and Todos Medical Ltd. (19.99%). Breakthrough has been assigned the intellectual property and other rights to the LymPro Test, a diagnostic blood test for Alzheimers disease, as well as rights to other neurological diagnostics testing intellectual property. Todos Medical has provided Amarantus with notice of Todos decision to exercise its exclusive option to acquire the 80.01% of Breakthrough Diagnostics that it currently does not own.

The Lymphocyte Proliferation Test (LymPro Test) determines the ability of peripheral blood lymphocytes (PBLs) and monocytes to withstand an exogenous mitogenic stimulation that induces them to enter the cell cycle. It is believed that certain diseases, most notably Alzheimer's disease, are the result of compromised cellular machinery that leads to aberrant cell cycle re-entry by neurons, which then leads to apoptosis. LymPro is unique in the use of peripheral blood lymphocytes as surrogates for neuronal cell function, suggesting a common relationship between PBLs and neurons in the brain.

About Todos Medical Ltd.Todos Medical Ltd. is an in-vitro diagnostic company engaged in the development of blood tests for the early detection of a variety of cancers, and also has initiated the development of blood tests for neurodegenerative disorders such as Alzheimer's disease through Breakthrough Diagnostics, Inc., its joint venture with Amarantus Bioscience Holdings, Inc. Todos has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancers influence on the immune system, which triggers biochemical changes in peripheral blood mononuclear cells and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The companys two cancer screening tests, TM-B1 and TM-B2, have received the CE mark. Breakthrough Diagnostics is developing the LymPro Test, a blood test for diagnosing Alzheimers disease.

For more information, the content of which is not part of this press release, please visithttp://www.todosmedical.com

About Amarantus Bioscience Holdings, Inc.Amarantus Bioscience Holdings (AMBS) is a JLABS alumnus biotechnology company developing treatments and diagnostics for diseases in the areas of neurology, regenerative medicine and orphan diseases through its subsidiaries. The Companys 80.01%-owned subsidiaryBreakthrough Diagnostics, Inc.,currently a joint venture with Todos Medical, Ltd., has licensed intellectual property rights to the Alzheimers blood diagnostic LymPro Test from Leipzig University that was originally developed by Dr. Thomas Arendt, as well as certain rights to multiple sclerosis diagnostic MSPrecise and Parkinsons diagnostic NuroPro. Amarantus entered into a joint venture agreement withTodos Medical, Ltd. to advance diagnostic screening assets and Todos has exercised its exclusive option to acquire Amarantus remaining ownership in Breakthrough in exchange for approximately 50% ownership of Todos. The transaction is expected close before the end of the first quarter of 2020. Amarantus also owns approximately 30% of the common shares of Avant Diagnostics, Inc., a healthcare data-generating technology company that specializes in biomarker assay services that target multiple areas of oncology. Avant provides precision oncology data through its TheraLink assays to assist the biopharmaceutical industry and clinical oncologists in identifying likely responders, initially for breast cancer, to over 70 FDA-approved drug treatments.

AMBS 50%-owned subsidiaryElto Pharma, Inc. has development rights to eltoprazine, a Phase 2b-ready small molecule indicated for Parkinson's disease levodopa-induced dyskinesia, Alzheimers aggression and adult attention deficit hyperactivity disorder, commonly known as ADHD. AMBS acquiredCutanogen Corporationfrom Lonza Group in 2015. Cutanogen is preparing for pivotal studies with Engineered Skin Substitute (ESS) for the treatment of pediatric life-threatening severe burns. ESS is a regenerative medicine-based, autologous full-thickness skin graft technology originally developed by the Shriners Hospital that can be used to treat severe burns, as well as several other catastrophic and cosmetic dermatological indications. AMBS wholly-owned subsidiary,MANF Therapeutics Inc.owns key intellectual property rights and licenses from a number of prominent universities related to the development of the therapeutic protein known as mesencephalic astrocyte-derived neurotrophic factor (MANF). MANF Therapeutics is developing MANF-based products as treatments for ophthalmological disorders such as Wolfram Syndrome, Retinitis Pigmentosa and Glaucoma, as well as neurodegenerative diseases such as Parkinsons disease. MANF was discovered by the Companys Chief Scientific Officer John Commissiong, PhD. Dr. Commissiong discovered MANF from AMBS proprietary discovery engine PhenoGuard, and believes several other neurotrophic factors remain to be discovered. Amarantus has entered into a binding letter of intent to license the therapeutic assets from Elto Pharma, Cutanogen and MANF Therapeutics to Emerald Organic Products.

Forward-looking StatementsCertain statements contained in this press release may constitute forward-looking statements. For example, forward-looking statements are used when discussing our expected clinical development programs and clinical trials. These forward-looking statements are based only on current expectations of management, and are subject to significant risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical does not undertake any obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, please refer to its reports filed from time to time with the U.S. Securities and Exchange Commission.

Todos Investor and Corporate Contact:Kim Sutton GolodetzLHA Investor RelationsSenior Vice President (212) 838-3777kgolodetz@lhai.com

Todos Corporate ContactDaniel HirschTodos MedicalInvestor RelationsEmail:Dan.h@todosmedical.comPhone: (347) 699-0029

Amarantus Investor and Media Contact:Gerald CommissiongPresident & CEOOffice: 650-862-5391Email: gerald@amarantus.com

More:
Todos and Amarantus JV Announces Full Enrollment for Clinical Trial of LymPro Alzheimer's Blood Test Relationship with Amyloid PET - GlobeNewswire

ONE man and his dog are travelling to North Carolina this week, to provide a puppy with a pioneering stem cell transplant that could save her life.

Robert Alcock and his cocker spaniel, Coco, are making the journey so Coco, 7, can donate her stem cells to one of her own puppies, Millie, 6, who has cancer.

The experimental procedure is not yet available in the UK and can only be performed at one US hospital, the NC State Veterinary Hospital.

It involves using stem cells from the bone marrow of one dog and injecting them into the other.

Even if the operation is a success, there is only a 50 percent chance that Millie will be cured.

Millie was taken to the USA when her owners, Serena and Andrew Lodge, emigrated for work. After moving across the pond, Millie contracted cancer.

Millie the dog last week and (inset) before she became ill

Mr Alcock, who lives in Darwen, said the only way to help her is the transplant.

The 52-year-old catering manager said: Serena and Andrew started chemo on Millie three months ago but theyve been told the only chance theyll have of curing her is if they find a positive donor so she can have a transplant.

They contacted us, and we sent some blood samples for testing, along with samples from one of Cocos other pups.

They both came back positive but because Coco is Millies mother the vet said she would be a better match.

Mr and Mrs Lodge then asked Mr Alcock if he would fly to the USA with Coco so she could help save Millies life.

On Wednesday, Mr Alcock made the journey to North Carolina, to the only animal hospital in the States that can perform that kind of transplant on dogs.

Mr Alcock added: The Lodges have paid for everything, and I didnt like to ask how much the operation is costing but I think it will be in the thousands.

We will be in America for about a week.

Coco will go into hospital on Sunday for the procedure and then the cells will be donated on Monday.

Coco is expected to make a full recovery from the operation, but there is only a 50 per cent chance that Millie could be cured once the transplant has been completed.

Robert and Coco

Mr Alcock added: If it was a human then the chances of survival would be really good.

But this is a pioneering procedure, they havent done very many of these transplants before, so well have to wait and see what happens.

See the original post here:
Cocker Spaniel Coco goes to US to try and save her puppy's life - Lancaster and Morecambe Citizen

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade. Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field. The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs. A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment. However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians. A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Follow this link:
Canine Stem Cell Therapy Market Unit Sales To Witness Significant Growth In The Near Future 2017-2026 - Zebvo

As per the research conducted by Fast. MR, the report titled Canine Arthritis Treatment Market by Treatment Type (Non-steroidal anti-inflammatory Medications (NSAIDs), Opioids and Stem Cell Therapy), By Route of Administration (Oral, and Injectables), By Distribution Channel (Veterinary Hospitals and Clinics, Retail Pharmacies and Online Pharmacies) and By Region (North America, Europe, Asia Pacific, Latin America, Middle East and Africa) Global Market Size, Development, Growth and Demand Forecast, 2018-2027 provides current as well as future analysis of the market by evaluating the major applications, advantages, trends, and challenges. The report dives deeper to produce useful insights into Canine Arthritis Treatment Market such as major global regions and key competitors and strategies that can be used for the entry-level player too.

Get Latest Sample for Canine Arthritis Treatment Market @ https://www.fastmr.com/request-s/100

Overview

Canine arthritis is a result of inflammation of the joints, ligament damage, abnormal cartilage development, or damage caused by trauma in dogs. Usually arthritis problem associated with older dogs, however it may occur at early age of dogs, who are facing bone and joint development problem. Arthritis symptoms include stiffness, lameness, or limping after rest; appetite loss or unusual weight gain; inactivity and sleeping more; reluctance to walk, run or climb stairs; unusual urinating in the house; and irritability and other behavioural changes. Since past, According to the American Pet Products Association (APPA), the adoption of pet animal has been increased at a significant rate, about 68% of U.S. households own at least one pet, which adds up to 60.2 Mn dogs and 47.1 Mn dogs, among other animals. Hence, there is a push to increase the standard of living for pets, including higher quality veterinary products. Further, in 2018, US$72.56 Bn was spent on pets, out of which US$ 33.5 Bn was spent for over-the-counter (OTC) medicine in the U.S. Thus, rising companion animal ownership with increase in spending for pet health is creating a growing demand for canine arthritis drugs.

Rising preference of gynaecologist for genetic testing during pregnancy is expected to propel the canine arthritis treatment market growth.

Significant increase in veterinary therapeutic drugs and veterinary regenerative medicines approvals by FDA to repair damaged organs and tissues in animals is expected to drive the canine arthritis treatment market growth. For instance, in November 2018, Chanelle launched Osteopen (pentosan polysulphate sodium) in the UK and Irish markets. Osteopenia is a semi-synthetic polymer with anti-inflammatory properties and capable of modifying the metabolism of the joint structures, which in turn helps to regenerate damaged joint components and reduces the pain.

Furthermore, increase in prevalence of osteoarthritis in dogs will expected to create a demand for canine arthritis drugs market in near future. According to Veterinary Science Development news, one in four of 77.2 million pet dogs in the U.S. are diagnosed with some form of arthritis.

However, certain risks associated with canine arthritis treatment and lack of awareness may restrain the canine arthritis treatment market growth to some extent.

Canine Arthritis Treatment Market Regional Analysis

On the basis of region, North America is gaining significant traction in the canine arthritis treatment market. This is attributed to increase in consumer spending on pet and easy accessibility of treatment and diagnostic methods. There are about 26,000 small animal veterinary practices in the U.S., according to American Animal Hospital Association (AAHA) and the American Veterinary Medical Association (AVMA) which result in a significant increase in veterinary economy the country.

Europe also contribute noteworthy growth in canine arthritis treatment market owing to launch of new treatment by various pharmaceutical companies for canine arthritis. For instance, on March 2019, Medrego, the manufacturer of veterinary regenerative medicine in Northern Europe has launched new Stem Cell Therapy product-CaniCell which has shown tremendous effects on managing osteoarthritis and other degenerative diseases in dogs.

Key players operating in the canine arthritis treatment markets include, Eli Lilly and Company, Boehringer Ingelheim, Chanelle, Zoetis Inc., Medrego, Vetoquinol S.A., Bayer AG, Aratana Therapeutics Inc., Norbrook Laboratories Limited, VetStem Biopharma, and Dechra Pharmaceuticals Plc, and others.

Canine Arthritis Treatment Market-Taxonomy

By Treatment Type

-Non-steroidal anti-inflammatory medications (NSAIDs)

-Opioids

-Stem Cell Therapy

By Route of Administration

-Oral

-Injectables

By Distribution Channel

-Veterinary Hospitals and Clinics

-Retail Pharmacies

-Online Pharmacies

By Region

-North America

-Europe

-Asia Pacific

-Latin America

-Middle East and Africa

Access Complete Canine Arthritis Treatment Market Report@ https://www.fastmr.com/report/100/canine-arthritis-treatment-market

About Us:

FAST.MR is a global market research and business-consulting organization that aims to provide a deep market insight to our clients, which helps them in better decision making in the dynamic environment. We have a team of highly qualified personnel that studies the market in depth to provide our clients with better strategies to stand out in the market.

Contact Us:

Jason Lee

150 State Street, Albany,

New York, USA 12207

+1 (518) 300-1215

Email: sales@fastmr.com

Website: http://www.fastmr.com

Follow Us Facebook, Twitter, Linked In

More https://fastmr.blogspot.com/

Read More https://marketresearchtab.com/

https://marketnewsbizz.com/

The rest is here:
Canine Arthritis Treatment Market 2018 to Showing Impressive Growth by 2027 | Industry Trends, Share, Size, Top Key Players Analysis and Forecast...

BURLINGAME, CA / ACCESSWIRE / November 12, 2019 / Humanigen, Inc., (OTC PINK:HGEN) ("Humanigen"), a clinical stage biopharmaceutical company focused on the development of next generation chimeric antigen receptor T cell (CAR-T) and other cell therapies, today announced that two abstracts supporting development of its next generation EphA3-CAR-T program, built on the backbone of ifabotuzumab, the company's proprietary Humaneered anti-EphA3 monoclonal antibody, have been accepted for presentation at the 2019 annual meeting of the Society for Neuro-Oncology (SNO) being held November 20-24, 2019 in Phoenix, AZ.

While CAR-T therapy has revolutionized the treatment landscape for hematological malignancies, its efficacy remains limited in solid tumors. The majority of CAR-T therapies targeting solid tumors have focused on cell surface receptors expressed on tumor cells. However, given the heterogeneity of surface receptor expression on solid tumors and the difficulty of navigating the immunosuppressive stromal microenvironment, strategies to target tumor neovasculature and tumor stromal cells are emerging. Targeting non-transformed, tumor neovasculature and tumor stroma cells may overcome antigen loss and may modulate the suppressive TME. EphA3, an oncofetal antigen, is selectively expressed in tumor neovasculature and tumor stromal cells in brain cancers and other solid tumors making it a novel target for CAR-T development.

The phase I clinical study, led by Prof. Hui Gan and Prof. Andrew Scott from the Olivia Newton-John Cancer Research Institute in Melbourne, Australia, was funded by the Cure Brain Cancer Foundation. The study used radiolabeled ifabotuzumab followed by sequential positron emission tomography (PET) imaging to determine biodistribution, frequency of in situ EphA3 expression and quantitative tumor uptake of ifabotuzumab. The preliminary results include data from eight patients who have been enrolled to date. PET/computed tomography (CT) imaging showed that ifabotuzumab is effectively delivered across the blood-tumor barrier and accumulates specifically at the tumor site in all patients treated to date with no observed normal tissue uptake. Magnetic resonance imaging (MRI) scans showed predominant T2/FLAIR changes, consistent with the treatment effect of ifabotuzumab on tumor vasculature. Treatment emergent adverse events were readily managed with increased premedications after the first occurrence. The abstract is available online at: https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi6/5619490?redirectedFrom=fulltext.

Professors Gan and Scott stated "Our results show that ifabotuzumab is safe and very effective at targeting the tumor. We are also excited that there are early indications that ifabotuzumab may help to control disease growth in some patients."

Using a single chain variable region fragment of ifabotuzumab, a second generation CD28 co-stimulated CAR construct was developed. Using primary patient derived GBM cell lines, the EphA3 CAR-T demonstrated specific and potent anti-tumor activity. Data from in vivo and combinatorial CAR-T experiments will be reported during the oral presentation scheduled on Friday, November 22, 2019 at 4:40pm. The abstract is available online at: https://academic.oup.com/neuro-oncology/article-abstract/21/Supplement_6/vi88/5619352?redirectedFrom=fulltext.

"These results indicate for the first time that targeting EphA3 with CAR-T cells is feasible, efficacious, and represents a novel therapeutic strategy for solid tumors" stated Dr. Cameron Durrant, CEO of Humanigen. "Our EphA3-CAR-T program as another pillar in our developing cell therapy pipeline. While we continue to develop our GM-CSF neutralization platform with Kite, we are also busy building next generation CAR-T therapies with our combinatorial GM-CSF gene-editing platform and our other CAR-T programs focused on novel tumor targets", Dr. Durrant continued.

About Humanigen, Inc.

Humanigen, Inc. is developing its portfolio of next-generation cell and gene therapies for the treatment of cancers via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. There is a direct correlation between the efficacy of CAR-T therapy and the incidence of life-threatening toxicities (referred to as the efficacy/toxicity linkage). We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. The company's immediate focus is combining FDA-approved and development stage CAR-T therapies with lenzilumab, the company's proprietary Humaneered anti-human-GM-CSF immunotherapy, which is its lead product candidate. A clinical collaboration with Kite, a Gilead Company, was recently announced to evaluate the sequential use of lenzilumab with Yescarta, axicabtagene ciloleucel, in a multicenter clinical trial in adults with relapsed or refractory large B-cell lymphoma. The company is also focused on creating next-generation combinatory gene-edited CAR-T therapies using strategies to improve efficacy while employing GM-CSF gene knockout technologies to control toxicity. In addition, the company is developing its own portfolio of proprietary first-in-class EphA3-CAR-T for various solid cancers and EMR1-CAR-T for various eosinophilic disorders. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). The company has established several partnerships with leading institutions to advance its innovative cell and gene therapy pipeline. For more information, visit http://www.humanigen.com

Story continues

About the Olivia Newton-John Cancer Research Institute

The Olivia Newton-John Cancer Research Institute is a leader in the development of experimental and breakthrough cancer treatments. We investigate and develop treatments for cancers of the breast, lung, skin, prostate, liver, gastrointestinal tract and brain. Our researchers and clinicians are running more than 120 clinical trials, giving patients access to potential new treatments including immunotherapies and personalized medicine.

Located in Heidelberg, Victoria, Australia, the Institute is integrated within the ONJ Centre, with research laboratories only metres away from where patients are cared for and receive treatment. This inspires and enables the rapid translation of scientific discovery into clinical trial of new, better, cancer treatments.

Forward-Looking Statements

This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for future development of lenzilumab to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in Black Horse Capital and its affiliates owning more than 50% of our outstanding common stock, including their ability to control the company; our lack of profitability and need for additional capital to operate our business as a going concern; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.

All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.

CONTACT:

Media:Chris Bowe(646) 662-7628cbowe@humanigen.com

SOURCE: Humanigen, Inc.

View source version on accesswire.com: https://www.accesswire.com/566037/Humanigen-Announces-Two-Abstracts-Accepted-at-the-2019-Annual-Meeting-of-the-Society-for-Neuro-Oncology-including-Oral-Presentation-on-its-Next-Generation-EphA3-CAR-T

Read the rest here:
Humanigen Announces Two Abstracts Accepted at the 2019 Annual Meeting of the Society for Neuro-Oncology, including Oral Presentation on its Next...

Share

Share

Share

Email

Overview

TMRs report on the Canine Stem Cell Therapy Market is an all-important tool for stakeholders in their pursuit to discover avenues for innovation, and further undertake strategic planning for the launch of products and services.

Our research report on the Canine Stem Cell Therapy Market serves as a valuable guide for stakeholders. The report deep dives into demand drivers, challenges, and opportunities that are likely to influence the Canine Stem Cell Therapy Market over the forecast period. These indicators help businesses pave way in a crowded business landscape, and tread ahead in the competition with confidence.

Further, the report carries out solid groundwork and divulges details ofs share of key segments of the under product, application, and geography.

To ascertain indicators, analysts employed proven research tools and techniques for the same. The analysis of indicators helps business carry out the most strategic planning for competitive advantage. These indicators also help businesses gauge investment proposition and scope of expansion in the Canine Stem Cell Therapy Market over the forecast period.

The report analyzes the competitive landscape of the Canine Stem Cell Therapy Market at length. The section includes detailed insights into key business strategies used by prominent players. Further, the report analyzes impact of growth strategies on the competitive dynamics and valuable insights into share projections of key players in the Canine Stem Cell Therapy Market over the forecast period.

If you are stakeholder in the Canine Stem Cell Therapy Market , the analysis provided will help you understand growth model. Click to get a Brochure report in PDF(including ToC, Tables and Figures).

The report includes an exhaustive list of prominent players in the Canine Stem Cell Therapy Market are VetStem Biopharma, Inc., Regeneus Ltd, Aratana Therapeutics, Inc., VETherapy Corporation, Animal Cell Therapies, Inc., Magellan Stem Cells, and Medrego..

For further know-how of competitive outlook, the report discusses SWOT analysis of prominent players, and how this will impact the competitive hierarchy until the end of the forecast period. This serves as a crucial intelligence indicator to gauge growth strategies adopted by stakeholders, and their stance on mergers, acquisitions, partnerships, and collaborations that can help remain competitive.

Key Questions Answered in the Canine Stem Cell Therapy Market Industry Report

See the original post here:
Canine Stem Cell Therapy Market Analysis and Forecast up to 2026 - Tech Admirers

Persistence Market Research (PMR) has published a new research report on canine stem cell therapy. The report has been titled, Canine Stem Cell Therapy Market: Global Industry Analysis 2016 and Forecast 20172026.Veterinary research has been used in regenerative and adult stem cell therapy andhas gained significant traction over the last decade. Canine stem cell therapy products are identified to have gained prominence over the past five years, and according to the aforementioned research report, the market for canine stem cell therapy will expand at a moderate pace over the next few years.

Though all animal stem cells are not approved by FDA, veterinary stem-cell manufacturers and university researchers have been adopting various strategies in order to meet regulatory approvals, and streamline and expedite the review-and-approval process. The vendors in the market are incessantly concentrating on research and development to come up with advanced therapy, in addition to acquiring patents.

In September 2017, VetStem Biopharma, Inc. received European patent granted to the University of Pittsburgh and VetStem received full license of the patent then. This patent will eventually provide the coverage for the ongoing commercial and product development programs of VetStem and might be also available for licensing to other companies who are rather interested in this field. The other companies operating in the global market for canine stem cell therapy are VETherapy Corporation, Aratana Therapeutics, Inc., Regeneus Ltd, Magellan Stem Cells, Animal Cell Therapies, Inc., and Medrego, among others.

According to the Persistence Market Research report, the globalcanine stem cell therapy marketis expected to witness a CAGR of 4.2% during the forecast period 2017-2026. In 2017, the market was valued at US$ 151.4 Mn and is expected to rise to a valuation of US$ 218.2 Mn by the end of 2026.

Burgeoning Prevalence of Chronic Diseases in Dogs to Benefit Market

Adipose Stem Cells (ASCs) are the most prevalent and in-demand adult stem cells owing to their safety profile, ease of harvest, and use and the ability to distinguish into multiple cell lineages. Most early clinical research is focused on adipose stem cells to treat various chronic diseases such as arthritis, tendonitis, lameness, and atopic dermatitis in dogs. A large area of focus in veterinary medicine is treatment of osteoarthritis in dogs, which becomes more prevalent with age. Globally, more than 20% dogs are suffering from arthritis, which is a common form of canine joint and musculoskeletal disease. Out of those 20%, merely 5% seem to receive the treatment. However, elbow dysplasia in canine registered a prevalence rate of 64%, converting it into an alarming disease condition to be treated on priority. Thereby, with the growing chronic disorders in canine, the demand for stem cell therapy is increasing at a significant pace.

Expensive Nature of Therapy to Obstruct Growth Trajectory

Expensive nature and limited access to canine stem cell therapy has demonstrated to be a chief hindrance forestalling its widespread adoption. The average tier II and tier III veterinary hospitals lack the facilities and expertise to perform stem cell procedures, which necessitates the referral to a specialty vet hospital with expertise veterinarians. A trained veterinary physician charges high treatment cost associated with stem cell therapy for dogs. Generally, dog owners have pet insurance that typically covers maximum cost associated with steam cell therapy to treat the initial injury but for the succeeding measures in case of retreatment, the costs are not covered under the pet insurance. The stem cell therapy is thus cost-prohibitive for a large number of pet owners, which highlights a major restraint to the market growth. Stem cell therapy is still in its developmental stage and a positive growth outcome for the market cannot be confirmed yet.

Read more here:
Canine Stem Cell Therapy Market is Anticipated to Expand at a Healthy CAGR of 4.2% Throughout the Forecast Quantity 2017-2026 - Zebvo

His quality of life was significantly improved and Oles owner noted that VetStem Cell Therapy exceeded her expectations.

POWAY, Calif. (PRWEB) November 05, 2019

Ole, a German Shepherd, was demonstrating signs of osteoarthritis in April 2019. He was lame and stiff and had difficulty with stairs and jumping. Though his energy level and his willingness to play were normal, it was clear that he was in pain.

Oles owner took him to veterinary surgeon Dr. Holly Mullen of VCA Emergency Animal Hospital and Referral Center in San Diego, California. Dr. Mullen is an experienced VetStem user and has provided VetStem Cell Therapy services for over sixty patients. Upon examination, Dr. Mullen diagnosed Ole with severe osteoarthritis in his hips as a result of hip dysplasia. In patients with joint dysplasia, the affected joint is malformed causing the bone to rub irregularly, which can eventually lead to osteoarthritis. Ole was also diagnosed with osteoarthritis in his lower, or lumbar, spine. It was apparent that these issues were causing Ole discomfort.

In an effort to provide relief, Dr. Mullen recommended Ole receive VetStem Cell Therapy. Adipose-, or fat-derived, stem cell therapy is used by veterinarians to treat osteoarthritis and soft tissue injuries. VetStem Cell Therapy utilizes a patients natural healing cells which may reduce inflammation, block pain, and regenerate damaged joint tissues.

To begin the process, Dr. Mullen extracted fat from Oles abdomen in a minimally invasive anesthetic procedure. The fat was delivered to the VetStem laboratory in Poway, California where it was received and aseptically processed by trained VetStem laboratory technicians. Oles stem cells were extracted and concentrated from his fat tissue and dosed out into an injection that was delivered back to Dr. Mullen. Within 48 hours of the initial fat collection, Ole received one intravenous injection of his own stem cells.

As a follow up to his first injection, Ole received additional stem cell injections approximately two months later. This time he received one injection into each hip, injections along the muscles in his back, as well as an intravenous injection.

In a 90-day post stem cell therapy evaluation (approximately 90 days after the first treatment), Oles owner reported that he was no longer stiff or painful. She also noticed an improvement in his ability to go up and down the stairs, walk, and jump. His quality of life was significantly improved and Oles owner noted that VetStem Cell Therapy exceeded her expectations.

Dr. Mullens findings were similar at the 90-day examination. She stated, He is doing great! He runs around [the owners] acreage every day with no overt lameness and no signs of painhes strongly ambulatory with a bouncy gait.

Like Ole, many dogs suffer from osteoarthritis and unfortunately, treatment options are somewhat limited. For these patients, VetStem Cell Therapy may be an option. According to owners and veterinarians, greater than 80% of dogs showed an improved quality of life after receiving VetStem Cell Therapy for orthopedic conditions. Stem cells are regenerative cells that can differentiate into many tissue types, reduce pain and inflammation, help to restore range of motion, and stimulate regeneration of tendon, ligament and joint tissues. In a peer-reviewed study of dogs with chronic osteoarthritis of the hip, it was found that stem cells reduced lameness and pain.

About Holly Mullen, DVM, DACVSDr. Mullen received her DVM from Virginia-Maryland Regional College of Veterinary Medicine in 1985. She completed a small animal medicine and surgery internship as well as a residency in small animal surgery at the Animal Medical Center in New York City. In 1990, she became a board-certified veterinary surgeon. Dr. Mullen has been providing VetStem Cell Therapy for over a decade.

About VetStem Biopharma, Inc.VetStem Biopharma is a veterinarian-led Company that was formed in 2002 to bring regenerative medicine to the profession. This privately held biopharmaceutical enterprise, based near San Diego, California, currently offers veterinarians an autologous stem cell processing service (from patients own fat tissue) among other regenerative modalities. With a unique expertise acquired over the past 15 years and 17,000 treatments by veterinarians for joint, tendon or ligament issues, VetStem has made regenerative medicine applications a therapeutic reality. The VetStem team is focused on developing new clinically practical and affordable veterinary solutions that leverage the natural restorative abilities present in all living creatures. In addition to its own portfolio of patents, VetStem holds exclusive global veterinary licenses to a large portfolio of issued patents in the field of regenerative medicine.

Share article on social media or email:

Visit link:
VetStem Biopharma Shares the Success Story of Ole who was Treated with VetStem Cell Therapy by Dr. Holly Mullen - PR Web

Canine Stem Cell Therapy market report includes the estimation of market size for value and volume. Further, the report explains statistical forecasts, major trends, regional marketing analysis, and Canine Stem Cell Therapy industry based on Strengths, Weaknesses, industry internal and external environments. Those data are further broken down with manufacturing base distribution, Canine Stem Cell Therapy production area and product type. Major points like market situation and trends, concentration rate mergers, expansion which is basic Canine Stem Cell Therapy information to grow/establish a business is also provided.

Companies operating in the Canine Stem Cell Therapy Market are focusing on merger and acquisitions and new product launches to gain competitive advantage. The Canine Stem Cell Therapy report offers accurately prepared statistics that show the comparison of the aforementioned estimations for all years of the forecast period 2019-2025. numerous factors area unit accountable for the Canine Stem Cell Therapy markets growth, that area unit studied well during this analysis report.

VETSTEM BIOPHARMA, Cell Therapy Sciences, Regeneus, Aratana Therapeutics, Medivet Biologics, Okyanos, Vetbiologics, VetMatrix, Magellan Stem Cells, ANIMAL CELL THERAPIES, Stemcellvet

Request for Free Sample Copy at: http://www.researchreportcenter.com/request-sample/1258647

United States, China, European Union, Rest of World (Japan, Korea, India and Southeast Asia)

Grab Attractive Discount on this report at: http://www.researchreportcenter.com/check-discount/1258647

Customization of the Report: This report can be customized as per your needs for additional data or countries.Please connect with our sales team (sales@researchreportcenter.com)

See the rest here:
Canine Stem Cell Therapy Market Trends and Analysis to (2019-2025) - Pledge Times

As concerns over antibiotic resistance grow, equine veterinarians look for ways to treat wounds without reaching for these powerful drugs. At the 2019 British Equine Veterinary Association Congress, held Sept. 11-14 in Birmingham, U.K., Dean Hendrickson, DVM, Dipl. ACVS, described ways to do just this, ranging from debridement to stem cell therapy.Debridement

The best way to deal with bacteria is to get rid of them, said Hendrickson, a professor in the Clinical Sciences Department at Colorado State Universitys Veterinary Teaching Hospital, in Fort Collins.

We have a tendency in veterinary medicine to want to kill the bacteria in situ, but Im going to encourage you to remove them and throw them away and dont let the patient have to deal with them at all, he advised the audience.

Veterinarians can remove bacteria through debridement (removing the affected tissue), of which there are several types:

Autolytic debridement. This process uses the bodys own enzymes and moisture to liquefy and remove necrotic (dead) tissue. Hendrickson said its the most selective way to remove bacteria and dead cells while leaving healthy cells.

All youre doing is leaving the healthy wound exudate (liquid the body produces in response to tissue damage) in contact with the wound bed to accomplish this, he said. The normal white blood cells and proteolytic enzymes that occur in wound exudate are your best friends with regard to removing small doses of bacteria and small amounts of necrotic tissue.

To achieve autolytic debridement, you must keep the wound environment moist (but not soupy), which you can do using dressings. If the wound has a lot of necrotic tissue, however, then youll need to use a more aggressive form of debridement, said Hendrickson.

Biological debridement. This method involves using an organism, such as maggots, to remove dead tissue.

It still amazes me how effective maggot debridement is and how rarely we actually use it, said Hendrickson. When a horse comes into the clinic with maggots in its wound, he said people tend to get squeamish and try to remove them, but these guys are doing their jobtheyre getting rid of the necrotic tissue (and pathogenic bacteria). Theres a lot of value to that, and its very rapid and selective.

Enzymatic (chemical) debridement. With this method, veterinarians apply manufactured proteolytic enzymes to the wound to break down devitalized tissue.

This is another great way (to debride wounds), but we dont tend to use it very frequently in veterinary medicine because of the cost of the enzymes, said Hendrickson. Studies have found it to be very effective at reducing bacteria but not as good as autolytic debridement. So the body in and of itself is the best way to go if you have low levels of bacteria.

Mechanical debridement. This technique involves using force to remove tissue. Examples include wet-to-dry dressings and wound irrigation. Its something we do really well in veterinary medicine, almost to a fault, he explained. We scrub, we lavage, and we cause a significant amount of trauma to the wound bed.

On the plus side, mechanical debridement is inexpensive and effective. The downside? It can cause shear stresses to the underlying granulation (scar) tissue, which can lead to further problems down the road, Hendrickson said.

He recommended using the minimal amount of force and pressure necessary.

Sharp debridement. This method involves using tools such as scalpels or curettes to physically remove tissue. Its the most aggressive form of debridement and the most effective way to remove large amounts of bacteria and necrotic tissue, said Hendrickson.

Theres a lot of value to wound debridementthat should be your first step toward reducing bacteria numbers and necrotic tissue, he said. We should not be bathing them with local or systemic antimicrobials. Remove the infected tissue thats there.

Veterinarians can use a variety of debridement dressings to help remove bacteria and dead tissue. Ones Hendrickson said are useful include:

Hypertonic saline. This solution comprises 20% saline, which you can buy commercially or make yourself using salt and water.

The idea is the hypertonic environment created by this saline will kill the bacteria because theyre unable to deal with that environment, and it will also remove the necrotic tissue, Hendrickson said.

While these are highly effective, he said theyre less selective than autolytic, biologic, or enzymatic dressings. He also cautioned against overusing them, because they have the potential to be toxic.

Honey. This substance is both hypertonic and antimicrobial. It can help heal burns, for instance, faster and with fewer adverse effects than other dressings, said Hendrickson.

Researchers have performed a variety of studies confirming the efficacy of honeys such as manuka honey. Further, said Hendrickson, theres some recent evidence out there that shows that local raw honey is more effective at killing local bacteria than medical grade honey.

Polyhexanides (e.g., polyhexamethylene biguanide, or PHMB). Certain sterile antimicrobial dressings are very effective at killing bacteria, even multidrug-resistant varieties. Theyre not antiseptics and should not be confused with them, said Hendrickson.

He then provided the audience with smart antibiotic use tips for when they do need these drugs to combat infection, starting with a sensitivity culture to identify the specific bacteria.

Whether its systemic or local antibiotic therapy, do a culture to know whats happening, then always use the simplest, lowest level of antibiotic possible, he said. While your first dressing might require using an antibiotic you cant pick because you dont know whats there, at least try to get a culture so you can make the decision later on.

Only use antibiotics for short periodstwo weeks or less, he said.

As for topical antibiotics, he recommended using silver dressings or, preferably, triple antibiotic, which hasnt seen much resistance over the decades its been in use.

Hendrickson also reviewed promising studies looking at mesenchymal (embryonic connective tissue) stem cell use in wound treatment: The one place there is evidence for stem cells is in the reduction of bacteria numbers in wounds.

There are lots of ways to reduce bioburden (number of bacteria) in wounds, said Hendrickson. I think wound debridement is the best way to accomplish that. Get rid of the necrotic tissue, and dont use antiseptics in your wounds, because they just create more necrosis, thereby encouraging the number of bacteria forming.

And if you do have to resort to antibiotic administration, choose your antimicrobials well, and use them sparingly, he said.

Go here to read the rest:
Managing Horse Wounds Without Antibiotics - TheHorse.com